Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-08-22
2006-08-22
Kaushal, Sumesh (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C435S455000
Reexamination Certificate
active
07094598
ABSTRACT:
The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.
REFERENCES:
patent: 6171596 (2001-01-01), Earl et al.
patent: 6200959 (2001-03-01), Haynes et al.
patent: WO 99/32147 (1999-07-01), None
patent: WO 01/16183 (2001-03-01), None
Lee at al, Eur J Biochem. 271(6):1094-105, 2004.
Pereira et al Nucleic Acids Res.28(3):663-668. 2000.
Aoki, K. et al. 1999 “Efficient generation of recombinant adenoviral vectors by Cre-lox recombinationin vitro,” Mol. Med.5:224-231.
Baize, S. et al. 1999 “Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients,”Nature Med.5:423-426.
Bray, M. et al. 1998 “A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever,”J. Infect. Dis.178:651-661.
Connolly, B.M. et al. 1998 “Pathogenesis of experimental Ebola virus infection in guinea pigs,”J. Infect. Dis.179:S203-S217.
Davis, A.R. et al. 1985 “Expression of hepatitis B surface antigen with a recombinant adenovirus,”PNAS USA82:7560-7564.
Feldmann, H. et al. 1994 “Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein,”Virology199:469-473.
Fisher-Hoch, S.P. et al. 1985 “Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola),”J. Infect. Dis.152:887-894.
Geisbert, T.W. et al. 2002 “Evaluation in nonhuman primates of vaccines against Ebola virus.”Emerg. Infect. Dis.8(5):503-507.
Hanke, T. et al. 1998 “Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime,”Vaccine16:439-445.
Kiley, M.P. et al. 1980 “Ebola virus: identification of virion structural proteins,”J. Gen. Virol.49:333-341.
Krieg, A.M. et al. 1995 “CpG motifs in bacterial DNA trigger direct B-cell activation,”Nature374:546-549.
Ksiazek, T.G. et al. 1992 “Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates,”J. Clin. Microbiol.30:947-950.
Letvin, N.L. et al. 1997 “ Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination,”PNAS USA94:9378-9383.
Maryuama, T. et al. 1999 “Ebola virus can be effectively neutralized by antibody produced in natural human infection,”J. Virol.73:6024-6030.
Natuk, R.J. et al. 1992 “Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model,”PNAS USA89:7777-7781.
Ohno, T. et al. 1994 “Gene therapy for vascular smooth muscle cell proliferation after arterial injury,”Science265:781-784.
Pushko, P. et al. 2001 “Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses,”J. Virol.75(23):11677-11685.
Robinson, H.L. et al. 1999 “Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations,”Nature Med.5:526-534.
Sanchez, A. et al. 1996 “The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing,”PNAS USA93:3602-3607.
Sanchez, A. et al. 1998 “Biochemical analysis of the secreted and virion glycoproteins of Ebola virus,”J. Virol.72:6442-6447.
Sato, Y. et al. 1996 “Immunostimulatory DNA sequences necessary for effective intradermal gene immunization,”Science273:352-354.
Schneider, J. et al. 1998 “Enhanced immunogenicity for CD8+T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara,”Nature Med.4:397-402.
Sedegah, M. et al. 1994 “Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein,”PNAS USA91:9866-9870.
Sedegah, M. et al. 1998 “Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine,”PNAS USA95:7648-7653.
Sullivan, N.J. et al. 2000 “Development of a preventive vaccine for Ebola virus infection in primates,”Nature408:605-609.
Sullivan, N.J. et al. 2000 “Ebola virus pathogenesis and vaccine development,” Symposium on Marburg and Ebola Viruses, Marburg, Germany, Oct. 1-4, 2000, Abstract 23, p. 35.
Sullivan, N.J. et al. 2003 “Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates,”Nature424:681-684.
Tang, D.C. et al. 1992 “Genetic immunization is a simple method for eliciting an immune response,”Nature356:152-154.
Ulmer, J.B. et al. 1993 “Heterologous protection against influenza by injection of DNA encoding a viral protein,”Science259:1745-1749.
Vanderzanden, L. et al. 1998 “DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge,”Virology246:134-144.
Wang, B. et al. 1993 “Gene inoculation generates immune responses against human immunodeficiency virus type 1,”PNAS USA90:4156-4160.
Wilson, J. et al. 2000 “Epitopes involved in antibody-mediated protection from Ebola virus,”Science287:1664-1666.
Xiang, Z.Q. et al. 1996 “A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier,”Virology219:220-227.
Xiang, Z.Q. et al. 1999 “Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant,”J. Immunol.162:6716-6723.
Xu, L. et al. 1998 “Immunization for Ebola virus infection,”Nature Med.4:37-42.
Yang, Z. et al. 1998 “Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins,”Science279:1034-1037.
Yang, Z. et al. 2000 “Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury,”Nature Med.6:886-889.
Yang, Z.Y. et al. 2003 “Overcoming immunity to a viral vaccine by DNA priming before vector boosting,”J. Virol.77(1):799-803.
Barouch, D.H. et al., 2005, “A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates,” J. Virol. 79:8828-8834.
Nabel Gary J.
Yang Zhi-yong
Kaushal Sumesh
Knobbe Martens Olson & Bear LLP
The United States of America as represented by the Department of
LandOfFree
Development of a preventive vaccine for filovirus infection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Development of a preventive vaccine for filovirus infection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Development of a preventive vaccine for filovirus infection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659269